Medical News

RSS

Foamix' emollient foam platform awarded Mexican patent

Foamix Ltd., a leading developer of topical foams for dermatological and gynecological use, announced today that it has been awarded Mexican Patent Registration No. 268451 entitled "Cosmetic and Pharmaceutical Foam." The patent covers Foamix's vehicles, compositions and cosmetic and pharmaceutical uses thereof based on the company's Emollient Foam technology platform.

4 Nov 2009

GenVec receives FDA orphan drug designation for TNFerade

GenVec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM) for the treatment of pancreatic cancer.

4 Nov 2009

MRG's new report on the European markets for small-joint reconstructive implants

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European market for small-joint reconstructive implants will double by 2014, reaching almost $360 million.

4 Nov 2009

Gastric cancer drug market to double to nearly $1.5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the gastric cancer drug market -- driven by the launch of several targeted agents over the next few years -- will more than double from approximately $700 million in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

4 Nov 2009

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.

4 Nov 2009

AGA Medical Holdings receives regulatory product approvals and licenses in China

AGA Medical Holdings, Inc. (AGA Medical) has received regulatory approvals and licenses in China for its AMPLATZER® PFO Occluder and AMPLATZER® Multi-Fenestrated Septal Occluder “Cribriform.”

4 Nov 2009

Conflicts of interest examined between doctors and medical industry, AARP and reform

Health care reform bills include provisions to examine the financial relationships between doctors and the medical industry while some are questioning the AARP's role in reform.

4 Nov 2009

Spray dryer strengthens PharmaForm's portfolio of bioavailability enhancement solutions

PharmaForm, a contract pharmaceutical development and manufacturing organization and a wholly owned subsidiary of Akela Pharma Inc. (TSX: AKL), today announced that it has added aqueous and solvent spray drying to its portfolio of bioavailability enhancement solutions.

4 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

PAH patients face life-threatening risks from medication errors

Pulmonary arterial hypertension (PAH) patients using infused drugs have suffered serious injury or in some cases died from medication errors in hospitals and other inpatient settings, according to a peer-reviewed study by Accredo Health Group and several university hospitals that surveyed doctors, nurses and pharmacists.

4 Nov 2009

GSK's malaria vaccine trial containing Antigenics’ Stimulon adjuvant enrolls more than 5,000 children

Antigenics, Inc. today indicated that GlaxoSmithKline’s (GSK) Phase III malaria vaccine clinical trial, containing Antigenics’ QS-21 Stimulon® adjuvant, has enrolled more than 5,000 children to date and is expected to involve up to 16,000 children. The pivotal efficacy study of RTS,S, the world’s most clinically advanced malaria vaccine, is ongoing in seven African countries.

4 Nov 2009

Watson Pharmaceuticals announces third quarter 2009 financial results

Watson Pharmaceuticals, Inc. today reported net income of $63.0 million, or $0.55 per diluted share for the third quarter ended September 30, 2009. Excluding special items as detailed in the reconciliation table below, adjusted net income for the third quarter was $76.1 million, or $0.66 per diluted share, an increase of $22.1 million or 41 percent over the adjusted net income for the third quarter ended September 30, 2008. As detailed in the attached reconciliation table, adjusted EBITDA for the third quarter was $178.4 million.

4 Nov 2009

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA.

4 Nov 2009

Spinal Modulation completes its $27.4 million Series C financing

Spinal Modulation, Inc. announced today the completion of its $27.4 million Series C financing. Johnson & Johnson Development Corporation (JJDC) joined existing major investors including DeNovo Ventures, ePlanet/DFJ, Kleiner Perkins Caufield & Byers, and MedVenture Associates in this financing. DFJ/InCube Ventures and Raffles Venture Partners are additional new investors.

4 Nov 2009

Over 425 hospitals implement Capsule's medical device connectivity solution

Capsule (www.capsuletech.com), the leading provider of medical device connectivity, today announced recent additions to its rapidly expanding list of hospitals that have implemented their solution.

4 Nov 2009

Third quarter 2009 financial results announced by Affymax

Affymax, Inc. today reported financial results for the third quarter ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million compared to a net loss of $26.2 million for the third quarter of 2008.

4 Nov 2009

Financial results for the third-quarter of 2009 announced by Almost Family

Almost Family, Inc., a leading regional provider of home health nursing services, announced today its financial results for the three months ended September 30, 2009.

4 Nov 2009

Shionogi files New Drug Application in Japan

BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this filing, BioCryst will receive a regulatory milestone payment of $7 million under its agreement with Shionogi.

4 Nov 2009

Garmin reports financial results for the third quarter of 2009

Garmin Ltd. today announced third quarter results for the period ended September 26, 2009.

From Garmin 4 Nov 2009

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has advanced to the RNAi therapeutic collaboration stage of its landmark alliance with Roche formed in 2007.

4 Nov 2009

Medical News

Foamix' emollient foam platform awarded Mexican patent

GenVec receives FDA orphan drug designation for TNFerade

MRG's new report on the European markets for small-joint reconstructive implants

Gastric cancer drug market to double to nearly $1.5 billion in 2018

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

AGA Medical Holdings receives regulatory product approvals and licenses in China

Conflicts of interest examined between doctors and medical industry, AARP and reform

Spray dryer strengthens PharmaForm's portfolio of bioavailability enhancement solutions

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

PAH patients face life-threatening risks from medication errors

GSK's malaria vaccine trial containing Antigenics’ Stimulon adjuvant enrolls more than 5,000 children

Watson Pharmaceuticals announces third quarter 2009 financial results

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Spinal Modulation completes its $27.4 million Series C financing

Over 425 hospitals implement Capsule's medical device connectivity solution

Third quarter 2009 financial results announced by Affymax

Financial results for the third-quarter of 2009 announced by Almost Family

Shionogi files New Drug Application in Japan

Garmin reports financial results for the third quarter of 2009

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News